ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Now for something a little different

<< Previous

Bullboard Posts

Next >>

Comment by Thenorth1990on Sep 17, 2021 3:49pm

100 Views

Post# 33879066

RE:RE:RE:RE:Now for something a little different

I believe. 08 was a result of aducanumab getting a thumbs down from the fda panel and uncertainty on funding. That is not there anymore. So won't be that bad . Still might see Lower sp if no further developments. Can't believe they can get away with not keeping us in loop about serology developments so far.

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week